Shukra Pharmaceuticals Limited Stock

Equities

SHUKRAPHAR6

INE551C01028

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:55 2024-05-27 am EDT 5-day change 1st Jan Change
109.1 INR -1.99% Intraday chart for Shukra Pharmaceuticals Limited -9.59% +252.55%
Sales 2022 205M 2.47M Sales 2023 595M 7.16M Capitalization 514M 6.19M
Net income 2022 7M 84.26K Net income 2023 44M 530K EV / Sales 2022 0.62 x
Net Debt 2022 32.91M 396K Net Debt 2023 11.08M 133K EV / Sales 2023 0.88 x
P/E ratio 2022
12.6 x
P/E ratio 2023
1.79 x
Employees 182
Yield 2022
0.83%
Yield 2023
1.07%
Free-Float 42.7%
More Fundamentals * Assessed data
Dynamic Chart
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Shukra Pharmaceuticals Limited Announces the Resignation of Jivansingh Gangasingh Negi as Independent Director CI
Shukra Pharmaceuticals Limited Announces Board Changes CI
Shukra Pharmaceuticals Limited Announces Directorate Resignations CI
Shukra Pharmaceuticals Limited Announces Executive Changes CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Shukra Pharmaceuticals Limited Announces Resignation of Ashvin Trivedi as Non- Executive Director, Effective August 12, 2023 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Shukra Pharmaceuticals Limited Announces Board Changes CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Shukra Pharmaceuticals Limited Approves Final Dividend for the Financial Year 2021-22 CI
More news
1 day-1.99%
1 week-7.75%
Current month+16.84%
1 month+19.14%
3 months+65.95%
6 months+382.72%
Current year+252.55%
More quotes
1 week
109.07
Extreme 109.07
118.23
1 month
91.55
Extreme 91.55
120.64
Current year
30.75
Extreme 30.75
120.64
1 year
20.43
Extreme 20.425
120.64
3 years
10.44
Extreme 10.44
120.64
5 years
6.16
Extreme 6.1625
120.64
10 years
6.16
Extreme 6.1625
120.64
More quotes
Managers TitleAgeSince
Director of Finance/CFO 27 20-05-10
Chairman 51 12-05-25
Compliance Officer - -
Members of the board TitleAgeSince
Chairman 51 12-05-25
Director/Board Member 43 12-05-22
Director/Board Member - 23-08-11
More insiders
Date Price Change Volume
24-05-27 109.1 -1.99% 5 238
24-05-24 111.3 -2.00% 7,170
24-05-23 113.6 -1.99% 6,127
24-05-22 115.9 -2.00% 7,629
24-05-21 118.2 -2.00% 25,426

Delayed Quote Bombay S.E., May 27, 2024 at 06:00 am EDT

More quotes
Shukra Pharmaceuticals Limited is an India-based company, which is engaged primarily in the business of manufacturing and marketing of pharmaceutical products. The Company operates in two sectors: pharmaceutical and laboratory. The Company's manufacturing plant is situated in Rakanpur, Gandhinagar. The Company's product portfolio includes antibiotics (penicillin), anti-biotics (cephalosporin), anti-biotics, macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, analgesic (NASID), muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic. The Company is engaged in manufacturing general formulations, such as tablets, capsules and small volume parenteral.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. SHUKRAPHAR6 Stock